1. Home
  2. JCE vs PRQR Comparison

JCE vs PRQR Comparison

Compare JCE & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

HOLD

Current Price

$16.88

Market Cap

288.2M

Sector

Finance

ML Signal

HOLD

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

SELL

Current Price

$1.44

Market Cap

262.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JCE
PRQR
Founded
N/A
2012
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.2M
262.5M
IPO Year
2007
2014

Fundamental Metrics

Financial Performance
Metric
JCE
PRQR
Price
$16.88
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $7.78
AVG Volume (30 Days)
29.6K
★ 934.7K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$8.25
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.99
$1.20
52 Week High
$17.45
$2.81

Technical Indicators

Market Signals
Indicator
JCE
PRQR
Relative Strength Index (RSI) 46.86 42.96
Support Level $16.70 $1.37
Resistance Level $17.21 $1.99
Average True Range (ATR) 0.20 0.10
MACD -0.02 0.01
Stochastic Oscillator 27.04 45.00

Price Performance

Historical Comparison
JCE
PRQR

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Share on Social Networks: